Extended indication Lokaal gevorderd, niet-resectabel NSCLC (stadium III)
Therapeutic value No estimate possible yet
Total cost 66,183,750.00
Registration phase No registration expected

Product

Registration

Therapeutic value

Expected patient volume per year

Expected cost per patient per year

Potential total cost per year

Off label use

Indication extension

Other information